Form 4: Q32 Bio Inc. CFO and President Lee Kalowski Reports Changes in Beneficial Ownership After Option Repricing

Lee Kalowski, CFO and President of Q32 Bio Inc., reports changes in beneficial ownership following an option repricing approved by the company's board of directors.

Summary

• On February 24, 2025, Lee Kalowski, CFO and President of Q32 Bio Inc., reported changes in beneficial ownership on Form 4.
• The changes include the acquisition of 53,250 shares of common stock and adjustments to stock options due to an option repricing.
• The board of directors approved an option repricing on February 24, 2025, which affected the terms of Kalowski's stock options.
• Kalowski acquired 16,901 and 161,323 stock options with an exercise price of $2.54.
• The restricted stock units vest in four equal installments over 36 months from the grant date.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing. The option repricing could be seen as a positive incentive for management, but it's not a major event.

Positives

• The option repricing could incentivize the reporting person to improve company performance.

Future Outlook

The restricted stock units vest over a 36-month period, contingent on continued service with the issuer.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• Shareholders are informed about changes in insider ownership.
• The option repricing may incentivize management to improve company performance, potentially benefiting shareholders.

Key Dates